143 related articles for article (PubMed ID: 30927666)
1. Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.
Gotfrit J; Jonker C; Zhang T; Goss G; Nicholas G; Laurie S; Wheatley-Price P
Cancer Treat Res Commun; 2019; 19():100130. PubMed ID: 30927666
[TBL] [Abstract][Full Text] [Related]
2. Patients With Advanced Non-Small Cell Lung Cancer Requiring Inpatient Medical Oncology Consultation: Characteristics, Referral Patterns, and Outcomes.
Gotfrit J; Zhang T; Zanon-Heacock S; Wheatley-Price P
Clin Lung Cancer; 2016 Jul; 17(4):292-300. PubMed ID: 26837473
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non-small-Cell Lung Cancer.
Dawe DE; Pond GR; Ellis PM
Clin Lung Cancer; 2016 Nov; 17(6):563-572.e2. PubMed ID: 27374398
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer in women, a different disease: survival differences by sex in Turkey.
Ulas A; Tokluoglu S; Kos M; Silay K; Akinci S; Oksuzoglu B; Alkis N
Asian Pac J Cancer Prev; 2015; 16(2):815-22. PubMed ID: 25684531
[TBL] [Abstract][Full Text] [Related]
5. Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
Brule SY; Al-Baimani K; Jonker H; Zhang T; Nicholas G; Goss G; Laurie SA; Wheatley-Price P
Lung Cancer; 2016 Jul; 97():15-21. PubMed ID: 27237022
[TBL] [Abstract][Full Text] [Related]
6. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
[TBL] [Abstract][Full Text] [Related]
8. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
9. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
[TBL] [Abstract][Full Text] [Related]
11. Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes.
Rittberg R; Green S; Aquin T; Bucher O; Banerji S; Dawe DE
Clin Lung Cancer; 2020 Sep; 21(5):e388-e404. PubMed ID: 32197856
[TBL] [Abstract][Full Text] [Related]
12. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.
Noonan K; Tong KM; Laskin J; Zheng YY; Melosky B; Sun S; Murray N; Ho C
Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):505-13. PubMed ID: 26095646
[TBL] [Abstract][Full Text] [Related]
14. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y; Ando M; Saka H; Chiba Y; Yamamoto N; Asami K; Hirashima T; Seto T; Nagase S; Otsuka K; Yanagihara K; Takeda K; Okamoto I; Aoki T; Takayama K; Yamasaki M; Kudoh S; Katakami N; Miyazaki M; Nakagawa K
J Thorac Oncol; 2013 Jun; 8(6):753-8. PubMed ID: 23575412
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Fujimoto D; Kato R; Morimoto T; Shimizu R; Sato Y; Kogo M; Ito J; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Tomii K
PLoS One; 2016; 11(12):e0168465. PubMed ID: 28006019
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Van Meerbeeck J; Galdermans D; Bustin F; De Vos L; Lechat I; Abraham I
Eur J Cancer Care (Engl); 2014 May; 23(3):370-9. PubMed ID: 24152297
[TBL] [Abstract][Full Text] [Related]
17. Analyzing the effect of physician assignment in the survival of patients with advanced non-small-cell lung cancer.
Wheatley-Price P; Jonker H; Al-Baimani K; Mhang T; Nicholas G; Goss G; Laurie SA
Curr Oncol; 2020 Feb; 27(1):34-38. PubMed ID: 32218658
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
[TBL] [Abstract][Full Text] [Related]
20. Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy.
Kim J; Cho CK; Yoo HS
Integr Cancer Ther; 2016 Dec; 15(4):467-477. PubMed ID: 27151594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
